Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety Study of Nexagon for Persistent Corneal Epithelial Defects

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Male and female subjects aged 18 years and over.~* Female subjects must be a) postmenopausal, b) surgically sterilized, c) practicing abstinence, or d) using a hormonal contraceptive, intrauterine device, diaphragm with spermicide, or condom with spermicide for the duration of the study.~* Subjects who are able to attend all follow-up visits and who are able to comply with all study procedures.~* Subjects who are willing and able to give written informed consent to take part in the study.~* Subjects with a PED, defined as follows: a corneal epithelial defect persisting for at least 14 days and not longer than 28 days.~* In the Investigator's opinion, the defect is persistent i.e., the defect has not shown improvement despite conventional treatment such as tear supplements and bandage contact lenses.~* The original defect to the cornea must have resulted from corneal epithelial debridement during diabetic vitrectomy surgery, HSV keratitis, HZV keratitis, corneal burns, post-PRK, or post-corneal transplant surgery.~Exclusion Criteria:~* Use of concomitant ocular medications in the screening period that are not specified in standardized PED treatment regimen~* Likely to require the use of concomitant ocular medications that are not specified in the standardized PED treatment regime during the study follow-up period~* Decrease or increase in the PED by more than 50% during the screening period.~* Have an active eyelid or ocular infectious process of any sort, in the opinion of the Investigator.~* Subjects with corneal perforation or impending corneal perforation.~* Subjects with severe eyelid abnormalities contributory to the persistence of the PED.~* Subjects with bilateral PED, if the smaller PED has a longest diameter of \> 2 mm. (Note: if bilateral PED is present and the smaller PED is \< 2 mm, the subject is eligible. In this situation only the eye with the larger PED should be entered into the study).~* Female subjects who are pregnant or breastfeeding. Female subjects who are neither postmenopausal nor surgically sterile require a negative urine pregnancy test on Day 0 (plus or minus 1 day) visit.~* Subjects who have a history of AIDS or HIV.~* Subjects with any other condition which, in the Investigator's opinion, would exclude the subject from participating.~* Treatment with systemic corticosteroids (equivalent to \> 10 mg/day of prednisone) or immunosuppressive or chemotherapeutic agents within 7 days prior to Day 0 (plus or minus 1 day) visit, or likely to receive one of these therapies during study participation~* Subjects who have participated in a clinical trial within 30 days prior to Day 0 (plus or minus 1 day) visit.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Nexagon (Type: ACTIVE_COMPARATOR): There will be 3 groups of patients with persistent epithelial defects, treated in a dose-escalation fashion from 1µg to 3µg to 10 µg. Each group will consist of 18 patients randomized to Nexagon and 6 patients randomized to placebo only.
- Vehicle only (Type: PLACEBO_COMPARATOR): There will be 3 groups of patients with persistent epithelial defects, treated in a dose-escalation fashion from 1µg to 3µg to 10 µg. Each group will consist of 18 patients randomized to Nexagon and 6 patients randomized to placebo only.

Based on this trial design, predict the completion outcome and termination type (if applicable).